Vol. 2 No. 2 (2022)
Reimbursement Recommendations

Estradiol (Imvexxy)

Published February 7, 2022

Key Messages

  • CADTH recommends that Imvexxy be reimbursed by public drug plans for the treatment of moderate-to-severe dyspareunia (painful sex) in women who are postmenopausal if certain conditions are met.
  • Imvexxy should only be covered in a similar manner as other vaginal estrogen products that include treatment of women who are postmenopausal and have moderate-to-severe painful sex.
  • Imvexxy should only be reimbursed if it is cost saving for drug programs compared to the least costly local hormone therapy reimbursed for the treatment of moderate-to-severe painful sex, a symptom of vulvar and vaginal atrophy (VVA) in women who are postmenopausal.